Last reviewed · How we verify
p53 gene
At a glance
| Generic name | p53 gene |
|---|---|
| Also known as | recombinant adenoviral human p53 gene |
| Sponsor | Shenzhen SiBiono GeneTech Co.,Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress
- Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL (PHASE1, PHASE2)
- Study of the Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage
- Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer
- Germline Genetic Testing of the TP53 Gene
- PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) (PHASE2)
- Metformin and Molecular Aging in Prediabetes (NA)
- Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- p53 gene CI brief — competitive landscape report
- p53 gene updates RSS · CI watch RSS
- Shenzhen SiBiono GeneTech Co.,Ltd portfolio CI